Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies

Carine Bossard, Elizabeth A. McMillan, Emily Creger, Brian Eastman, Chi-Ching Mak, Darrin M. Beaupre, Michael A. White

Blood (2021) 138 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2021-151305

Published: 2021

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 1377.

https://doi.org/10.1182/blood-2019-130500

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 4059.

https://doi.org/10.1182/blood-2019-124812

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 3913.

https://doi.org/10.1182/blood-2019-131209

Published: 2019

Journal Articles

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Gerlinde Wernig, MD, Michael G. Kharas, PhD, Rachel Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas, Chi Ching Mak, Glenn Noronha, Michael Martin, Yon D. Ko, Benjamin H. Lee, Richard Soll, Ayalew Tefferi, John D. Hood, D. Gary Gilliland

Blood (2007) 110 (11): 556.

https://doi.org/10.1182/blood.V110.11.556.556

Published: 2007

Journal Articles

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, MS, Annelie Abrahamsson, MS, Charlene Barroga, PhD, Edward Kavelerchik, MD, Jason R. Gotlib, MD MS, John D. Hood, PhD, Jeffrey Durocher, PhD, Chi Ching Mak, PhD, Glen Noronha, PhD, Richard Soll, PhD, Ayalew Tefferi, MD, Kenneth Kaushansky, MD, Catriona H.M. Jamieson, MD PhD

Blood (2007) 110 (11): 1526.

https://doi.org/10.1182/blood.V110.11.1526.1526

Published: 2007

Journal Articles

TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.

Betty Tam, PhD, Chi Ching Mak, Ph.D., Silva Stoughton, B.Sc., Cyrus Virata, B.Sc., Dan Lohse, Ph.D., Ehab Hanna, M.Sc., Marcela Alomia, B.Sc, Catriona Jamieson, MD., Ph.D., John Doukas, Ph.D., Glenn Noronha, Ph.D., Michael Martin, Ph.D., Richard Soll, Ph.D., John Hood, Ph.D.

Blood (2007) 110 (11): 898.

https://doi.org/10.1182/blood.V110.11.898.898

Published: 2007

Journal Articles

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Animesh Pardanani, MD, PhD, John Hood, PhD, Terra Lasho, Glenn Noronha, PhD, Christy Finke, Chi Ching Mak, PhD, Ruben Mesa, MD, Hong Zhu, PhD, Richard Soll, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2680.

https://doi.org/10.1182/blood.V108.11.2680.2680

Published: 2006

Journal Articles

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

John Hood, PhD, Jon Cao, PhD, Ehab Hanna, MS, Dan Lohse, PhD, Chi Ching Mak, PhD, Andrew McPherson, PhD, Glenn Noronha, PhD, Joel Renick, MS, Binqi Zheng, PhD, Hong Zhu, PhD, Richard Soll, PhD

Blood (2006) 108 (11): 3632.

https://doi.org/10.1182/blood.V108.11.3632.3632

Published: 2006

NARROW

The Pan-Clk/Dyrk Inhibitor Cirtuvivint (SM08502) Exposes Mechanistic Underpinnings of Alternative Splicing As a Therapeutic Vulnerability in Heme Malignancies

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Selective Inhibition of JAK2 Driven Erythroid Differentiation of Polycythemia Vera Progenitors

TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only